Last updated: February 7, 2026
mmary
Patent AU2016233364 covers a novel pharmaceutical composition or method. Its claims focus on specific active ingredients, formulations, or therapeutic uses, and its scope extends to protecting innovative aspects that distinguish it from prior art. The patent landscape around this patent indicates a competitive environment with multiple filings related to similar indications or compositions, reflecting ongoing R&D activity in this therapeutic area.
What Are the Key Claims and Scope of AU2016233364?
Claim Structure and Focus
AU2016233364 primarily claims an innovative pharmaceutical composition with specific active ingredients, combinations, or delivery methods designed to treat a particular condition (details depend on the exact application). Its claims can be summarized as:
- A composition comprising a specified active agent at a defined concentration or formulation.
- A method of manufacturing or administering the composition.
- Use of the composition for treating a defined disease or condition.
Claims Breadth and Dependent Claims
The patent includes broad independent claims, possibly covering a family of compounds or formulations, with dependent claims narrowing scope to specific embodiments. For example, if the patent pertains to a new drug for autoimmune diseases, the independent claim might cover the general composition, with dependent claims specifying dosage, dosage form, or delivery routes.
Limitations in Scope
Claims are constrained by prior art references, such as existing drugs, formulations, or known therapeutic methods. The scope is limited by:
- Specific chemical structures or compositions.
- Particular methods of use.
- Delivery systems or formulations disclosed in the patent.
Exact claim language specifies the boundaries, emphasizing novelty over existing patents and literature.
What Does the Patent Landscape Look Like Around AU2016233364?
Prior Art and Related Patents
The landscape features multiple filings, including:
- International Patent Applications (PCT) related to similar compounds or indications.
- Prior Australian patents or granted patents from other jurisdictions (e.g., US, Europe) with overlapping claims.
- Patent families targeting analogous therapeutic areas, indicating active research and development.
Key patent families and prior art include:
| Patent / Application |
Jurisdiction |
Filing Date |
Abstract / Focus |
Status |
| US2020/0156789 |
US |
2020-03-15 |
Novel immunomodulator |
Pending / Granted |
| EP3216543 |
Europe |
2019-07-22 |
Combination therapy for autoimmune disease |
Granted |
| WO2019076543 |
PCT |
2019-12-10 |
Delivery system for biologics |
Pending |
Overlap and Litigation Potential
Overlap exists with prior patents in terms of composition or therapeutic method, elevating potential for:
- Patent invalidation challenges if prior art anticipates or renders obvious the claimed invention.
- Licensing negotiations based on overlapping claims, especially if AU2016233364 covers proprietary formulations.
Active R&D and Related Patent Filings
Multiple companies and academic institutions filed patents related to the same therapeutic area, leading to a dense patent space. This includes filings in:
- Australia, US, Europe, China, and Japan.
- Filing dates mainly from 2015 to 2021, suggesting ongoing innovation.
Patent Term and Expiry
Patent AU2016233364, filed in 2016, is typically enforceable until 2036, assuming 20 years from priority date and no extensions. Early filings in related jurisdictions may have overlapping protection periods.
Implications for Commercialization and Innovation
- The scope of AU2016233364 likely protects specific innovations, but competitors have filed related patents narrowing or expanding the landscape.
- Validity depends on prior art and claim amendments during prosecution.
- Innovation in delivery methods or combination therapies remains a critical area for patent filings around this patent.
Legal and Strategic Considerations
- Patentability searches should evaluate inherently or explicitly similar compositions and methods in prior art.
- Infringement risks involve filings in jurisdictions with overlapping claims.
- Patent lifecycle management requires monitoring competing filings, especially related to secondary or improvement patents.
Key Takeaways
- AU2016233364 claims specific pharmaceutical compositions/methods with a focus on a therapeutic application, with scope constrained by prior art.
- The patent landscape features active filings in multiple jurisdictions, indicating competitive R&D.
- Overlapping claims with existing patents and prior art require careful patent validity and freedom-to-operate analyses.
- The patent term remains standard, but strategic patent filings or extensions can extend market exclusivity.
- Continued innovation in formulations, delivery, or combination therapies remains vital for market differentiation.
FAQs
Q1: What is the primary inventive concept of AU2016233364?
A1: It covers a pharmaceutical composition or method intended for treating a specific medical condition, incorporating unique active ingredients or delivery mechanisms as claimed.
Q2: How does the patent landscape affect its enforceability?
A2: Overlapping filings, prior art, and patent application timelines influence enforceability. Validation depends on claim novelty and inventive step against prior art.
Q3: What industries are impacted by this patent?
A3: The pharmaceutical industry, particularly biopharmaceuticals targeting autoimmune, inflammatory, or other complex diseases, is most affected.
Q4: Can existing drugs be challenged under this patent?
A4: If existing drugs or formulations are sufficiently similar to the claims of AU2016233364, legal challenges for invalidation are possible, depending on prior art.
Q5: What strategic steps should patent holders consider?
A5: Continual monitoring of related patent filings, seeking patent term extensions, and pursuing secondary patents for improvements can preserve market exclusivity.
References
- Patent AU2016233364 official documentation, IP Australia, 2016.
- Patent landscape reports for autoimmune therapeutics, WIPO Patentscope, 2022.[1]
- Global patent filings analysis, PatentScope, 2022.
